Cogstate announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate?s support of clinical trials in Alzheimer?s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer?s disease drug development?gained from leading global trials and programs?to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments.
Dr. Sink will also play a critical role in Cogstate?s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare. Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer?s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences.
Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer?s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.
